Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$26.39 USD

26.39
3,241,068

+0.03 (0.11%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $26.40 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trina Mukherjee headshot

Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More

by Trina Mukherjee

The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.

XRAY vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat

by Zacks Equity Research

Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.

LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat

by Zacks Equity Research

LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.

DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results benefit from strong segmental performance.

Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 9.23% and 6.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Aug 5 Earnings Roster: BDX, RMD & More

by Trina Mukherjee

Let's see how Medical Product companies' stocks like BDX, RMD, CAH, ABMD and XRAY are poised ahead of their earnings releases.

Should You Buy DENTSPLY SIRONA (XRAY) Ahead of Earnings?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Pharmaceutical segment.

Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

3 Stocks to Tap the Promising Dental Supplies Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

Debanjana Dey headshot

Dental Space Gains Momentum in 2021: 4 Stocks to Invest in

by Debanjana Dey

Dental stocks like Henry Schein (HSIC), Align Technology (ALGN), Straumann Holding (SAUHF) and DENTSPLY SIRONA (XRAY) are expected to continue their run over the next few months.

DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.

All You Need to Know About Dentsply (XRAY) Rating Upgrade to Buy

by Zacks Equity Research

Dentsply (XRAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.

Sejuti Banerjea headshot

Large-Cap Stocks Bring Stability to Your Portfolio

by Sejuti Banerjea

Large-caps bring stability to your portfolio because they don't react as aggressively to news and other events.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.

Dentsply International (XRAY) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 30.91% and 10.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed recovery in rapid immunoassay revenues during Q1.